Good morning and welcome to the 2026 Special Meeting of Summit Therapeutics Inc. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and we are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's investor relations website for updates. At this time, I would like to introduce Summit's chairman and Co-Chief Executive Officer, Bob Duggan.
Thank you, and good morning, ladies and gentlemen. It is my pleasure to welcome each of you to the 2026 Summit Therapeutics special meeting. From our management team today, we have Dr. Maky Zanganeh, our Co-Chief Executive Officer, President, and a member of our Board of Directors, Manmeet Soni, our Chief Operating Officer and Chief Financial Officer, and a member of our Board of Directors, as well as Dave Gancarz, our Chief Business and Strategy Officer. We also have Adam Finerman, a member of our external counsel team from BakerHostetler. Dave Gancarz will act as secretary of the meeting and will advise us on certain procedural items. Dave?
Good morning. Today's presentation, as well as the rules of conduct, are available in the meeting materials section on the virtual meeting website. Also available is the proxy statement. To submit a question, cast your vote, or view meeting information, select the corresponding icon in the panel located on the right side of your screen. To open a different panel, first close the panel you currently have open, then select the corresponding icon. Before we begin, I would like to remind everyone that except for statements of historical facts, some statements made by our management team and some responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law. Now, our chairman will describe how we will conduct the meeting.
First, there are some statements that must be made regarding the mailing of notice of the meeting and presence of a quorum. Then there is one matter to be voted on. Upon the report on the votes, we will answer questions in accordance with special meeting rules of conduct. Please hold any questions you may have until such time. The secretary has available for inspection a list of stockholders entitled to vote. Mr. Secretary, please advise us concerning the mailing of the proxy statement. Dave?
Mr. Chairman, the notice of special meeting and the proxy statement were mailed on or about October 19, 2026, to all stockholders of record as of the close of business on October 1st, 2026. We have appointed Adam Finerman, an attorney at our outside counsel, BakerHostetler, to be the inspector of election. If anyone is planning on voting during this meeting, please follow the instructions received regarding voting at the meeting. The inspector of election will report as to a quorum.
Thank you. Mr. Chairman, proxies have been received totaling a majority of the total votes entitled to be cast, constituting a quorum. This meeting is being held pursuant to the notice of special meeting, which was mailed to all stockholders of record as of the close of business on October 1st, 2026.
Thank you. I declare that this 2026 Summit Therapeutics special meeting is duly and legally convened. The voting on all matters will be by stockholders present and the stockholders represented by proxy. The items of business to be voted on will be set forth in the proxy statement. The first and only item of business is a proposal to amend the company's restated certificate of incorporation to increase the number of authorized shares of common stock by 1 billion, from 1 billion to 2 billion. At this time, any stockholders of record who wish to vote at the meeting should complete their voting. If you have already completed a proxy, there is no need to complete a ballot in order to vote. The polls for the matter to be voted on at this meeting are hereby declared open.
If any stockholder who wishes to vote at the meeting has not submitted his or her votes and needs more time, please so indicate. All votes are now in. I declare polls closed. The inspector of election has taken charge of the ballots cast and will tabulate the vote and submit a report in writing to the secretary. I will now turn matters over to the secretary to describe the preliminary report of the election results prepared by inspector of elections. Dave?
Mr. Chairman, the inspector of the election has presented me with his preliminary report. It has been determined that the amendment to the company's restated certificate of incorporation has been approved. We intend to disclose the final results on Form 8-K within four business days of this meeting. Once filed, a link to the Form 8-K will be available on our website under the Investor Information, Reports and Filings tab. Thank you.
Thank you very much. In accordance with the report of the inspector, I hereby affirm that such report has been accepted and ask that the secretary record such in the minutes of this meeting that he will prepare. The business of this meeting has now been completed, and I declare that the 2026 Summit Therapeutics special meeting is now concluded. With our formal business completed, I hereby adjourn our 2026 special meeting of stockholders. With that, I want to leave time for any questions from our shareholders.
At this time, we do not have any questions.
Yeah, and I am in receipt of no questions. With that, I want to thank you very much for attending our 2026 special meeting. Have a wonderful rest of your day. Thank you.
This concludes today's meeting. Thank you all for joining. You may now disconnect. Everyone, have a great day.